Table 1.

Baseline Characteristics of the Study Patients (n = 1,389)

Demographics
Age (y)	57 (45–65)
Sex (male/female)	594 (42.8)/795 (57.2)
Body mass index (kg/m2)	27.4 (24.8–30.6)
Diabetes mellitus (no/yes)	887 (63.9)/502 (36.1)
Hypertension (no/yes)	807 (58.1)/581 (41.9)
Dyslipidemia (no/yes)	589 (42.4)/800 (57.6)
Laboratory values
Platelet count (103/μL)	215 (175–263)
Alanine aminotransferase (IU/L)	73 (47–110)
Aspartate aminotransferase (IU/L)	51 (35–74)
Gamma-gultamyl transpeptidase (IU/L)	60 (40–99)
Albumin (g/dL)	4.4 (4.1–4.6)
Total bilirubin (mg/dL)	0.8 (0.6–1.0)
aMAP score	51.3 (44.2–56.9)
aMAP score (0–50/50–60/60–100)	620 (45.3)/545 (39.8)/203 (14.8)
FIB-4 index	1.55 (0.90–2.62)
FIB-4 index (<1.30/1.30–2.67/>2.67)	589 (42.4)/469 (33.8)/330 (23.8)
ALBI score	−2.96 (−3.18 to −2.70)
ALBI grade (≤ −2.60 / > −2.60 and ≤ −1.39 / > −1.39)	1126 (83.2)/226 (16.7)/2 (0.1)
Histology
Steatosis (0/1/2/3)	8 (0.6)/974 (70.1)/271 (19.5)/136 (9.8)
Inflammation (0/1/2/3)	67 (4.8)/879 (63.3)/364 (26.2)/79 (5.7)
Ballooning (0/1/2)	452 (32.5)/611 (44.0)/326 (23.5)
NAS score	4 (3–5)
NAS score (1–2/3–4/5–8)	280 (20.2)/747 (53.8)/362 (26.1)
Fibrosis stage (0/1/2/3/4)	240 (17.3)/536 (38.6)/394 (28.4)/195 (14.0)/24 (1.7)
NASH (no/yes)	459 (33.0)/930 (67.0)

Data are expressed as medians (interquartile range) or n (%).